The Latest Cardiac and Vascular News
REDWOOD CITY, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) — Avinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for the transfer of its listing from The Nasdaq Global Market to […]
REDWOOD CITY, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) — Avinger(NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, has successfully treated the first seven patients with the next generation Pantheris Lumivascular atherectomy system. Dr. Schwindt, an experienced operator […]
REDWOOD CITY, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced the Company submitted a new 510(k) application to the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment […]
REDWOOD CITY, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité Européenne (CE) Marking approval for its next generation Pantheris Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment of PAD. The novel design features of the next […]
REDWOOD CITY, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the Lumivascular approach to treating vascular disease, announced today it has entered into an agreement with CRG to waive compliance by Avinger with the […]
Beleaguered Avinger, Inc. is slashing more jobs. In its latest financial disclosure, Avinger reported a 61 percent decline in sales since the same time last year and would continue its strategic reorganization to save cash. The company said headcount has been reduced to 73 employees as of Oct. 15. That number includes 20 members of its sales […]
REDWOOD CITY, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) — Avinger(NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the third quarter of 2017 after the close of trading on Thursday, November 9, 2017. The Company will host a corresponding conference call beginning at […]
REDWOOD CITY, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced initiation of INSIGHT, a prospective, global, single arm, multi-center study to evaluate the safety and effectiveness of the Pantheris® Lumivascular Atherectomy System for treating in-stent restenosis (ISR) in lower extremity […]
REDWOOD CITY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the Pantheris® Lumivascular atherectomy system. In-stent restenosis occurs when a previously blocked artery treated with a stent becomes narrowed again, […]
SAN DIEGO & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Avinger, Inc. (NasdaqGM: AVGR) on behalf of all purchasers of Avinger securities pursuant to the company’s initial public offering on January 30, 2015 (the “Offering”), for alleged violations of the Securities Act of 1933 by […]
